EUCTR2008-008202-52-AT进行中（未招募）1 期
DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE - REMARC
YSARC0 个研究点目标入组 725 人开始时间: 2010年8月26日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 725
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For patients registered at the time of initial diagnosis:
- •Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including clinical subtypes (primitive mediastinal, intravascular, etc.). Patients with De Novo Transformed DLBCL from low grade lymphoma (Follicular, other..) may also be included. Patients with DLBCL associated with some small cell infiltration in bone marrow may also be included
- •- Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma
- •- Or CD20+ Follicular lymphoma grade 3B
- •- Or CD20+ Agressive B-cell lymphoma unclassifiable
- •Previously untreated with chemo- or radiotherapy
- •For patients registered after response evaluation to first line treatment with R-CHOP:
- •Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including clinical subtypes (primitive mediastinal, intravascular, etc.). Patients with De Novo Transformed DLBCL from low grade lymphoma (Follicular, other...) may also be included. Patients with DLBCL associated with some small cell infiltration in bone marrow may also be included
- •- Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma
- •- Or CD20+ Follicular lymphoma grade 3B
- •- Or CD20+ Agressive B-cell lymphoma unclassifiable
- •Have reached a CR or PR (Cheson 2007) after first line treatment with at least 6 cycles of R-CHOP-14 regimens and up to 8 cycles of R-CHOP-21
- •Previously untreated with Radiotherapy
- •For all patients:
- •Aged from 60 to 80 years at time of registration
- •Ann Arbor stages II-IV at time of initial diagnosis
- •aaIPI = 1 at time of initial diagnosis
- •Eastern Cooperative Oncology Group [ECOG] performance status 0-2
- •Minimum life expectancy of 3 months
- •Voluntary signed informed consent before performance of any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •The following laboratory values at screening
- •?Absolute neutrophil count (ANC) = 1 000.106/L and Platelets = 60 000.106/L, unless these abnormalities are related to bone marrow infiltration.
- •?Aspartate transaminase (AST) = 5 x ULN; Alanine transaminase (ALT) = 5 x ULN; Total bilirubin = 1.5 x ULN;
- •?Creatinine clearance > 30 ml/min (as calculated by the Cockcroft-Gault formula)
- •Females of childbearing potential (FCBP)† must:
- •?Have a negative medically supervised pregnancy test prior to starting of study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the patient practices complete and continued sexual abstinence.
- •?Either commit to continued abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy.
- •Male patients must:
- •?Agree to use a condom during sexual contact with a FCBP, even if they have had a vasectomy, throughout study drug therapy, during any dose interruption and after cessation of study therapy.
- •?Agree to not donate semen or s
排除标准
- •For all patients:
- •Any other histological type of lymphoma, Burkitt included.
- •Any history of treated or non-treated small B-cell lymphoma
- •Central nervous system or meningeal involvement by lymphoma
- •Contraindication to any drug contained in the chemotherapy regimen For example: cardiac contra-indication to anthracyclines (alteration of Left Ventricular Function defined by LVEF<50%) neurological contra-indication to vincristine (peripheral neuropathy of WHO grade = 2).
- •Myocardial infarction during last 3 months or unstable coronary disease or uncontrolled chronic symptomatic congestive heart insufficiency NYHA III - IV
- •Uncontrolled hypertension
- •Uncontrolled diabetes mellitus as defined by the investigator
- •Active systemic infection requiring treatment.
- •Previously known HIV positive serology
- •Active hepatitis B or C
- •Prior history of malignancies other than lymphoma within 3 years (except for complete resection of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy. Patients previously diagnosed with prostate cancer are eligible if (1) their disease was T1-T2a, N0, M0, with a Gleason score = 7, and a prostate specific antigen (PSA) = 10 ng/mL prior to initial therapy, (2) they had definitive curative therapy (ie, prostatectomy or radiotherapy) = 2 years before Day 1 of Cycle 1, and (3) at a minimum 2 years following therapy they had no clinical evidence of prostate cancer, and their PSA was undetectable if they underwent prostatectomy or <1 ng/mL if they did not undergo prostatectomy.
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
研究者
相似试验
进行中（未招募）
1 期
STUDY OF LENALIDOMIDE IN MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH B CELL LYMPHOMA AND PREVIOUSLY TREATED WITH R-CHOPDiffuse Large B Cell LymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-008202-52-PLYSARC650
进行中（未招募）
1 期
DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINEEUCTR2008-008202-52-PTYSARC650
进行中（未招募）
1 期
STUDY OF LENALIDOMIDE IN MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH B CELL LYMPHOMA AND PREVIOUSLY TREATED WITH R-CHOPDiffuse Large B Cell LymphomaMedDRA version: 20.0 Level: PT Classification code 10012818 Term: Diffuse large B-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-008202-52-BEYSARC725
进行中（未招募）
3 期
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)Diffuse large B cell lymphoma (DLBCL) in elderly patientsCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12611000085976Australasian Leukaemia and Lymphoma Group54
进行中（未招募）
1 期
Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.ntreated Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-022445-20-GRBristol-Myers Squibb International Corporation862